James Moore on Muck Rack

James Moore

Verified
Richmond
As seen in: Patient Worthy, EIN News, Plymouth Live, Neurology, Mad In America, The Horse Magazine, Independent en Español, IWCE's Urgent Communications, WHATNEXT.com
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with James

Contact James, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Alec and Stephen Baldwin Help Raise Over $250,000 at The Baldwin Fund Gala - Then Alec Hits Travel Trouble Getting Home

|
By James Moore 
| EIN News
Beth Baldwin, Alec Baldwin, “Charlie” Bross (family of Baldwin Grant Honoree Natalie Marie Arnold), and Stephen Baldwin at The Baldwin Fund Gala on Nov. 7, 2025, at the Marriott Syracuse Downtown, Syracuse, N.Y. (Provided photo by Kim Wolfe | The Baldwin Alec Baldwin faces post-gala travel delays after helping raise $250K for breast cancer research benefiting Upstate Medical University. This cause is deeply personal to my family.
Open in Who Shared View Duplicates (93) Issue with article?

Heart Health Heroes Wanted: Join a Clinical Trial to Help Manage ATTR-CM

|
By James Moore 
| Patient Worthy
Acknowledgment: This story is sponsored by Alexion Pharmaceuticals and is promoted through the Patient Worthy Collaborative Content program. We only publish content that embodies our mission of providing relevant, vetted, and valuable information to the rare disease community. A new clinical trial called the DepleTTR-CM study is underway to understand a potential new treatment for transthyretin amyloid cardiomyopathy (ATTR-CM).
Open in Who Shared Issue with article?
|
By James Moore 
| Patient Worthy
Acknowledgment: This story is sponsored by Alexion Pharmaceuticals and is promoted through the Patient Worthy Collaborative Content program. We only publish content that embodies our mission of providing relevant, vetted, and valuable information to the rare disease community. A new clinical trial called the DepleTTR-CM study is underway to understand a potential new treatment for transthyretin amyloid cardiomyopathy (ATTR-CM).
Open in Who Shared Issue with article?
See all 1,234 licensed articles (1,240 Total)

Actions

Share this page

Get in touch with James

Contact James, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified